“…FXTAS symptom presentation and timing are variable, and several studies have suggested that a “prodromal” phase, characterized by structural brain changes and subclinical social-emotional, cognitive, and motor issues may be detectable prior to clinically-observable symptoms ( Wang et al, 2012 , Loesch et al, 2015 , Gossett et al, 2016 , Wang et al, 2017 , McKinney et al, 2019 , Park et al, 2019 ). Quantitative markers of core sensorimotor and brain system differences representing prodromal FXTAS are needed to better understand disease course, identify degenerative processes during early stages, and to track and eventually mitigate disease progression, as has been done in other neurological disorders ( Rowe et al, 2010 , González-Garcia et al, 2011 , Trujillo et al, 2015 ).…”